New biologic: Soliris

April 2007
Formulary;Apr2007, Vol. 42 Issue 4, p215
Academic Journal
The article reports on the approval of recombinant monoclonal antibody eculizumab from Alexion Pharmaceuticals Inc. for the treatment of paroxysmal nocturnal hemoglobinuria to reduce hemolysis. Its efficacy is evaluated in a randomized placebo-controlled 26-week study, and a single-arm 52-week study. Moreover, it is recommended to give meningococcal vaccination, before administering the first dosage of eculizumab, to avoid infection.


Related Articles

  • American Society of Hematology.  // BioWorld Today;12/8/2009, Vol. 20 Issue 235, p6 

    The article reports on the new data offered by Alexion Pharmaceuticals Inc. which showed that paroxysmal nocturnal hemoglobinuria (PNH) was improved by Soliris in patients with no history of prior blood transfusions. The new data revealed that those patients with PNH demonstrated increased...

  • ALEXION REACHES AGREEMENT WITH FDA FOR PHASE III ECULIZUMAB.  // Biotech Business;Sep2004, Vol. 17 Issue 9, p5 

    Reports on the agreement of the U.S. Food and Drug Administration on the protocols constituting the phase III program of Alexion Pharmaceuticals Incorporated for its drug eculizumab. Overview of the phase III trial program; Results of the first trial performed on patients with chronic orphan...

  • CHMP ADOPTS POSITIVE OPINION FOR ALEXION'S SOLIRIS IN EUROPE.  // Worldwide Biotech;Jun2007, Vol. 19 Issue 6, p5 

    The article reports that the Committee for Human Medicinal Products of the European Medicines Agency has adopted a positive opinion recommending marketing authorization for Soliris, a drug from Alexion Pharmaceuticals Inc. The drug is for patients with paroxysmal nocturnal hemoglobinuria (PNH)....

  • Efficacy of Eculizumab in a Patient with Paroxysmal Nocturnal Hemoglobinuria Requiring Transfusions 14 Years after a Diagnosis in Childhood. Ueda, Takahiro; Hayakawa, Jun; Yamanishi, Miho; Maeda, Miho; Fukunaga, Yoshitaka // Journal of Nippon Medical School;2013, Vol. 80 Issue 2, p155 

    Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired clonal disorder characterized by chronic complement-mediated hemolysis. The humanized anti-C5 antibody eculizumab binds to the C5 protein and suppresses hemolysis by inhibiting C5b-9 generation. Here, we report on a 27-year-old woman...

  • Alexion, Others Show Resilience After Breakouts. KEN SHREVE // Investors Business Daily;12/3/2014, pB08 

    Stocks that show resilience and trade tightly after a are worth watching. Why? Because price action like this can often a new entry after an initial breakout.

  • Alexion Defies Biotech's Slow Sales Trend; Beats Estimates.  // Bioworld Week;7/25/2011, Vol. 19 Issue 30, p5 

    The article reports on the slow sales trend of drug Soliris (eculizumab) manufactured by Alexion Pharmaceuticals Inc. of Cheshire, Connecticut for the treatment of paroxysmal nocturnal hemoglobinuria.

  • Alexion Pharmaceuticals. Investor's Business Daily // Investors Business Daily;4/13/2015, pA02 

    The article focuses on the approval given to Alexion Pharmaceuticals Inc. (ALXN) which will allow update of the label of its drug Soliris for paroxysmal nocturnal hemoglobinuria to include patients without history of transfusion.

  • Recently Approved.  // Pharmaceutical Representative;May2007, Vol. 37 Issue 5, p14 

    The article presents the different drugs recently approved by the U.S. Food and Drug Administration. Humira of Abbott Laboratories Inc. has been denoted to reduce signs and symptoms of severely active Crohn's diseases in adults. UCB's Keppra has been authorized as adjunctive therapy in the...

  • First quadrivalent meningitis vaccine gets FDA nod.  // Drug Topics;2/7/2005, Vol. 149 Issue 3, p10 

    Reports on the U.S. Food and Drug Administration's approval of the meningococcal polysaccharide diphtheria toxoid conjugate vaccine, Menactra manufactured by Sanofi Pasteur for the prevention of meningococcal disease.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics